FORSHAG MARK,WALTRIP ROYCE,GARLINGHOUSE LES,BARNETT WILLIAM
申请号：
NZ62159612
公开号：
NZ621596A
申请日:
2012.11.22
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Discloses the use of Alpha1-proteinase inhibitor (A1PI) in the manufacture of a medicament for diminishing progression of one or more of a first set of symptoms associated with a pulmonary disease or disorder from worsening and/or increasing in severity in a subject in need thereof comprising: identifying the subject as in need of diminishing progression of said one or more of the first set of symptoms associated with a pulmonary disease or disorder from worsening and/or increasing in severity by identifying one or more of a second set of symptoms predictive of the pulmonary disease or disorder, wherein the second set of symptoms comprises: i) an increased cough ii) a change in sputum iii) decreased appetite and/or decreased weight iv) a change in respiratory examination and/or respiratory rate wherein said medicament comprises an effective amount of (A1PI) and is to be administered to said identified subject via inhalation prior to onset of said one or more of the first set of symptoms, wherein the first set of symptoms comprises: (a) shortness of breath (b) fatigue (c) a chronic cough (d) a reduction in forced expiratory volume (FEV1) and (e) decline in expiratory gas markers of respiratory inflammation and wherein the administration is to be carried out at least daily for a plurality of months.
